CA2560055A1 - Method of inducing or modulating immune response - Google Patents
Method of inducing or modulating immune response Download PDFInfo
- Publication number
- CA2560055A1 CA2560055A1 CA002560055A CA2560055A CA2560055A1 CA 2560055 A1 CA2560055 A1 CA 2560055A1 CA 002560055 A CA002560055 A CA 002560055A CA 2560055 A CA2560055 A CA 2560055A CA 2560055 A1 CA2560055 A1 CA 2560055A1
- Authority
- CA
- Canada
- Prior art keywords
- axotrophin
- polynucleotide
- polypeptide
- derived
- encoded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000028993 immune response Effects 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims description 74
- 230000001939 inductive effect Effects 0.000 title description 6
- 101710168832 E3 ubiquitin-protein ligase MARCHF7 Proteins 0.000 claims abstract description 212
- 102100023147 E3 ubiquitin-protein ligase MARCHF7 Human genes 0.000 claims abstract description 210
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 150
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 142
- 229920001184 polypeptide Polymers 0.000 claims abstract description 139
- 239000000427 antigen Substances 0.000 claims abstract description 81
- 108091007433 antigens Proteins 0.000 claims abstract description 81
- 102000036639 antigens Human genes 0.000 claims abstract description 81
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 136
- 108091033319 polynucleotide Proteins 0.000 claims description 136
- 239000002157 polynucleotide Substances 0.000 claims description 136
- 210000004027 cell Anatomy 0.000 claims description 102
- 108090000623 proteins and genes Proteins 0.000 claims description 79
- 230000014509 gene expression Effects 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 53
- 230000000694 effects Effects 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 210000000987 immune system Anatomy 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 6
- 238000002405 diagnostic procedure Methods 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000013068 control sample Substances 0.000 claims description 5
- 230000003389 potentiating effect Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108700008625 Reporter Genes Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 abstract description 11
- 238000003556 assay Methods 0.000 abstract description 6
- 239000002773 nucleotide Substances 0.000 abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 abstract description 4
- 108091007340 MARCHs Proteins 0.000 abstract description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 42
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 42
- 101100129373 Mus musculus Marchf7 gene Proteins 0.000 description 39
- 230000001105 regulatory effect Effects 0.000 description 34
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 23
- 210000004989 spleen cell Anatomy 0.000 description 19
- 210000000130 stem cell Anatomy 0.000 description 18
- 102000008070 Interferon-gamma Human genes 0.000 description 17
- 108010074328 Interferon-gamma Proteins 0.000 description 17
- 229960003130 interferon gamma Drugs 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000033228 biological regulation Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 102000001398 Granzyme Human genes 0.000 description 8
- 108060005986 Granzyme Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000016571 aggressive behavior Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000006058 immune tolerance Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 230000004043 responsiveness Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 5
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 102000008179 Cyclin B2 Human genes 0.000 description 4
- 108010060387 Cyclin B2 Proteins 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 125000001151 peptidyl group Chemical group 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 238000011749 CBA mouse Methods 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000008076 immune mechanism Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 230000003614 tolerogenic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000015097 RNA Splicing Factors Human genes 0.000 description 2
- 108010039259 RNA Splicing Factors Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 2
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- -1 antibody Proteins 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004287 null lymphocyte Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000003134 paneth cell Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 1
- 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 1
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 1
- 102100029672 E3 ubiquitin-protein ligase TRIM7 Human genes 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000233600 Glycine albicans Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000978673 Homo sapiens E3 ubiquitin-protein ligase MARCHF7 Proteins 0.000 description 1
- 101000795296 Homo sapiens E3 ubiquitin-protein ligase TRIM7 Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 101150107363 Lif gene Proteins 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710094505 Metallothionein-2 Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004053 Proto-Oncogene Proteins c-ets Human genes 0.000 description 1
- 108010018070 Proto-Oncogene Proteins c-ets Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100025902 RNA-binding protein 3 Human genes 0.000 description 1
- 101710133263 RNA-binding protein 3 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 description 1
- 101710190353 Splicing factor 3B subunit 1 Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010077674 Tetraspanin 25 Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- SYKWLIJQEHRDNH-CKRMAKSASA-N glutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-CKRMAKSASA-N 0.000 description 1
- SYKWLIJQEHRDNH-KRPIADGTSA-N glutaryl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-KRPIADGTSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 102000051412 human MARCHF7 Human genes 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000014725 late viral mRNA transcription Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001414 neuropoietic effect Effects 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 208000034280 venom allergy Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402051.7A GB0402051D0 (en) | 2004-01-29 | 2004-01-29 | Fate determination in immunity |
| GB0402051.7 | 2004-01-29 | ||
| PCT/EP2005/000934 WO2005074973A2 (en) | 2004-01-29 | 2005-01-31 | Method of inducing or modulating immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2560055A1 true CA2560055A1 (en) | 2005-08-18 |
Family
ID=31971742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002560055A Abandoned CA2560055A1 (en) | 2004-01-29 | 2005-01-31 | Method of inducing or modulating immune response |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070286807A1 (https=) |
| EP (1) | EP1713495A2 (https=) |
| JP (1) | JP2007523640A (https=) |
| KR (1) | KR20070007291A (https=) |
| CN (1) | CN1929855A (https=) |
| AU (1) | AU2005210105A1 (https=) |
| CA (1) | CA2560055A1 (https=) |
| GB (1) | GB0402051D0 (https=) |
| WO (1) | WO2005074973A2 (https=) |
| ZA (1) | ZA200606331B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402051D0 (en) * | 2004-01-29 | 2004-03-03 | Metcalfe Su | Fate determination in immunity |
| DK1826279T3 (da) * | 2006-02-28 | 2011-09-05 | Charite Universitaetsmedizin | Detektering og kvalitetskontrol af regulatoriske t-celler vha. DNA-metyleringsanalyse af FoxP3--genet |
| GB0614536D0 (en) * | 2006-07-21 | 2006-08-30 | Metcalfe Susan M | Methods of controlling cellular response to LIF |
| GB0721081D0 (en) * | 2007-10-26 | 2007-12-05 | Metcalfe Susan M | Immuno-modulatory composition |
| CA2770237A1 (en) * | 2009-08-05 | 2011-02-10 | Nexigen Gmbh | Human hcv-interacting proteins and methods of use |
| WO2014031883A1 (en) | 2012-08-23 | 2014-02-27 | Susan Marie Metcalfe | Neurotherapeutic nanoparticle compositions and devices |
| US11369473B2 (en) | 2019-04-08 | 2022-06-28 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| US11779683B2 (en) * | 2019-04-08 | 2023-10-10 | Loubert S. Suddaby | Extended release immunomodulatory implant to facilitate bone morphogenesis |
| CN112843222B (zh) * | 2021-01-21 | 2023-01-31 | 暨南大学 | Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| AU2003213606A1 (en) * | 2002-03-01 | 2003-10-13 | Exelixis, Inc. | MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| GB0402051D0 (en) * | 2004-01-29 | 2004-03-03 | Metcalfe Su | Fate determination in immunity |
-
2004
- 2004-01-29 GB GBGB0402051.7A patent/GB0402051D0/en not_active Ceased
-
2005
- 2005-01-31 US US10/587,995 patent/US20070286807A1/en not_active Abandoned
- 2005-01-31 ZA ZA200606331A patent/ZA200606331B/xx unknown
- 2005-01-31 CN CNA2005800072757A patent/CN1929855A/zh active Pending
- 2005-01-31 AU AU2005210105A patent/AU2005210105A1/en not_active Abandoned
- 2005-01-31 CA CA002560055A patent/CA2560055A1/en not_active Abandoned
- 2005-01-31 EP EP05707096A patent/EP1713495A2/en not_active Withdrawn
- 2005-01-31 KR KR1020067017432A patent/KR20070007291A/ko not_active Withdrawn
- 2005-01-31 WO PCT/EP2005/000934 patent/WO2005074973A2/en not_active Ceased
- 2005-01-31 JP JP2006550132A patent/JP2007523640A/ja not_active Withdrawn
-
2007
- 2007-10-17 US US11/873,586 patent/US20080125390A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070007291A (ko) | 2007-01-15 |
| WO2005074973A3 (en) | 2005-12-08 |
| WO2005074973A9 (en) | 2006-10-26 |
| JP2007523640A (ja) | 2007-08-23 |
| US20080125390A1 (en) | 2008-05-29 |
| US20070286807A1 (en) | 2007-12-13 |
| WO2005074973A2 (en) | 2005-08-18 |
| CN1929855A (zh) | 2007-03-14 |
| GB0402051D0 (en) | 2004-03-03 |
| AU2005210105A1 (en) | 2005-08-18 |
| ZA200606331B (en) | 2007-12-27 |
| EP1713495A2 (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080125390A1 (en) | Methods for Modulating Immune and Inflammatory Responses | |
| Zhang et al. | Tumour necrosis factor‐α (TNF‐α) transgene‐expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T‐cell activation and anti‐tumour immunity than DCs generated in recombinant TNF‐α | |
| KR20220100913A (ko) | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법 | |
| CN103930123A (zh) | 可溶性介体 | |
| US20210000921A1 (en) | Methods and compositions for modulating thymic function | |
| Dalton et al. | IMMUNOMONITORING OF RENAL TRANSPLANT RECIPIENTS IN THE EARLY POST-TRANSPLANT PERIOD BY SEQUENTIAL ANALYSIS OF CHEMOKINE AND CHEMOKINE RECEPTOR GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) | |
| Pietrzyk et al. | Quantitative gene expression analysis of fractalkine using laser microdissection in biopsies from kidney allografts with acute rejection | |
| Fan et al. | A NOVEL TOOL FOR B CELL TOLERANCE RESEARCH: CHARACTERIZATION OF MOUSE ALLOANTIBODY DEVELOPMENT USING A SIMPLE AND RELIABLE CELLULAR ELISA TECHNIQUE. | |
| Katayama et al. | PHENOTYPE AND FUNCTIONAL IDENTITY OF GM-CSF INDEPENDENT DENDRITIC CELLS GENERATED BY LONG-TERM PROPAGATION OF DC PROGENITOR CELLS IN BONE MARROW CELLS AND SKIN LANGERHANS CELLS | |
| Zhang et al. | PREVENTION OF OBLITERATIVE BRONCHIOLITIS BY JAK 3 INHIBITION WITH CP-690,550 IS ACCOMPANIED BY A DISTINCT GROWTH FACTOR GENE EXPRESSION PROFILE. | |
| Maksymowicz et al. | Recipient immature dendritic cells do not prolong allograft survival | |
| Zhou et al. | Endogenous C3 expression affects the potency of macrophages as stimulators of T cell alloreactivity | |
| Ushigome et al. | GITR activation in donor specific transfusion accelerates allograft rejection | |
| Yang et al. | The potential role of allograft inflammatory factor 1 (AIF-1) in macrophage activation in small-for-size liver transplantation | |
| Guo et al. | Inducing Donor-Specific Tolerance To Islet Allografts In Diabetic Nod Mice by Posttransplant Donor Lymphocyte Infusion | |
| Bentlejwesky et al. | KINETICS OF T CELL MEMORY RECOVERY IN LUNG TRANSPLANT RECIPIENTS TREATED WITH T CELL DEPLETION THERAPIES | |
| Yin et al. | THE ROLE OF IFN-γ INDUCERS (IL-18 AND IL-12 FAMILY) IN CHRONIC ALLOGRAFTS NEPHROPATHY | |
| Daniel et al. | CIRCULATING INTERLEUKIN-10-PRODUCING DENDRITIC CELLS ARE ASSOCIATED WITH HIGH INTERFERON-γ, IL-2, AND IL-3, AND LOW IL-10 IN PLASMA OF RENAL TRANSPLANT RECIPIENTS | |
| Azimzadeh et al. | MODULATION OF IMMUNE RESPONSES TO HEART ALLOGRAFTS BY DONOR BONE MARROW INFUSION IN MONKEYS TREATED WITH CD154 COSTIMULATION BLOCKADE | |
| Xavier et al. | MIG/CXCL9 IS SIGNIFICANTLY UPREGULATED IN CULTURES OF FINE-NEEDLE ASPIRATION BIOPSY SAMPLES OF ACUTELY REJECTING KIDNEY TRANSPLANT RECIPIENTS. | |
| Iwai et al. | REGULATION OF TH1 OR TH2 CYTOKINES PRODUCED BY NKT CELLS IN CYCLOPHOSPHAMIDE (CP)-INDUCED TOLERANCE | |
| Wyburn et al. | MACROPHAGE-DERIVED INTERLEUKIN-18 IN ACUTE RAT RENAL ALLOGRAFT REJECTION. | |
| Iwai et al. | GENERATION OF NKT-DEPENDENT AND INDEPENDENT REGURATORY T CELLS IN CYCLOPHOSPHAMIDE (CP)-INDUCED TOLERANCE | |
| Tomita et al. | INSIGNIFICANT ROLE OF DONOR NKT CELLS IN THE INDUCTION AND MAINTENANCE OF CYCLOPHOSPHAMIDE (CP)-INDUCED TOLERANCE | |
| Tokita et al. | LIVER SINUSOIDAL ENDOTHELIAL CELLS ENDOCYTOSED ALLOGENEIC CELLS TOLERIZE T CELL RECOGNIZING ALLO-ANTIGENS THROUGH INDIRECT RECOGNITION BY FAS-FAS LIGAND PATHWAY. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |